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Increased Serum Antibody Titer against HPV-16 Antigen in 
Patients with Behçet’s Disease
Quadrivalent human papillomavirus (HPV) vaccine has been reported to be significantly 
associated with Behçet’s disease (BD). However, no reports have described HPV infection as 
a possible cause for the development of BD. The objective of this study was to evaluate 
whether anti-HPV immunoglobulin G (IgG) antibody titer is increased in BD. Serum 
samples from 93 Korean BD patients, who fulfilled the diagnostic criteria of the 
International Study Group for BD, were used in an enzyme-linked immunosorbent assay 
(ELISA). The clinical activity of BD was evaluated at the time of blood sampling. HPV-16 L1 
virus-like particle (VLP) antigen was used in this study for the ELISA. Patients with BD had 
significantly higher antibody titers against HPV-16 (optical density [OD], 0.210–3.675; 
mean 0.992) than that of healthy controls (OD, 0.248–0.762; mean 0.517; P < 0.001). 
Using a receiver operating characteristic (ROC) analysis, a cut-off value of 0.578 OD for 
the anti-HPV antibody titer was determined that differentiated BD patients from healthy 
controls. When we compared the clinical features of BD between the 2 groups, articular 
involvement of BD was more likely in patients with an anti-HPV-16 antibody titer < 0.578 
OD (P = 0.035). In addition, patients with an anti-HPV-16 antibody titer < 0.578 were 
significantly younger than those with a titer ≥ 0.578 OD. HPV itself may be a possible 
extrinsic triggering infectious agent causing the development of BD.
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INTRODUCTION
Behçet’s disease (BD) is a chronic, recurrent, multisystem vas-
culitis with 4 cardinal symptoms, including oral ulcers, genital 
ulcers, skin lesions, and eye lesions. Besides these cardinal symp-
toms, central nervous system symptoms, vasculitis, arthritis, 
gastrointestinal symptoms, and epididymitis can be associated 
with the disease as minor symptoms. As a result of vasculitis, 
BD is a prothrombotic state which can cause superficial and 
deep venous thromboses, arterial aneurysms and occlusion 
(1,2). Even though various causes such as genetic factors, infec-
tions, and pollutants, have been proposed as potential causes 
for BD pathogenesis, the exact cause still remains to be eluci-
dated.
 After the introduction of bivalent and quadrivalent human 
papillomavirus (HPV) vaccination, postlicensure studies showed 
interesting data. Although the HPV vaccine is generally safe and 
well tolerated, issues about autoimmune disease was reported. 
It was a report on the rate of autoimmune, neurological, and 
venous thromboembolic adverse events after immunization of 
adolescent girls in Denmark and Sweden with the quadrivalent 
HPV vaccine. In this report, exposure to the quadrivalent HPV 
vaccine was associated with Raynaud’s disease and type 1 dia-
betes. The quadrivalent HPV vaccine, in particular, was signifi-
cantly associated with BD (3).
 This means that either an HPV antigen, an immunostimulant 
contained in the vaccine, or an aberrant immune response of 
the host could be important initiators in the development of 
BD. Otherwise, HPV infection could be another plausible cause 
of BD development.
 As there are some reports about related with BD and infec-
tions, we hypothesized HPV infection is related with BD. The 
objective of this study was to evaluate whether the anti-HPV 
antibody titer is increased in BD.
MATERIALS AND METHODS
Patients
A total of 93 Korean BD patients, who visited the BD Specialty 
Clinic at Severance Hospital and fulfilled the diagnostic criteria 
of the International Study Group for BD were recruited (mean 
age 42.85 ± 11.25 years; M/F 22/71). Healthy controls of 40 sub-
jects were enrolled who visited our hospital for health checkup 
without active infectious disease (mean age 47.13 ± 8.95 years; 
M/F 18/22). Each subjects of both group had no history of any 
type of HPV vaccine. All serum samples were kept in a −70°C 
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freezer and thawed at room temperature before use.
Assessment of disease activity
The clinical activity of BD was evaluated at the time of blood 
sampling. Two general assessment tools for the disease activity, 
the Behçet Disease Current Activity Form (BDCAF) and the elec-
tronic medical record (EMR)-based activity index (EMRAI) score, 
were used in this study. We used the latest version of the BDCAF 
(http://www.behcet.ws/behcetwsData/Uploads/files/Behcets-
DiseaseActivityForm.pdf; last accessed: on 26 January, 2016) in 
this study. The EMRAI is a simplified activity measurement form 
for BD, which was validated by its good correlation with the BD-
CAF (16). In brief, the EMRAI score was calculated as the sum 
of one point for each of 9 findings/symptoms (oral and genital 
ulcers, ocular symptoms, skin lesions, epididymitis, and symp-
toms related to the joints, gastrointestinal tract, vascular system, 
and the central nervous system), and an additional one point 
was added if a symptom was a new event. An elevated erythro-
cyte sedimentation rate (ESR) and C-reactive protein (CRP) val-
ue above their reference levels would also each increase the EM-
RAI score by one point. Because practical cut-off values to de-
fine ‘active disease’ for BD are not currently available, we de-
fined BD as being in the active phase if the patient presented 
with ≥ 2 major criteria according to the revised criteria of the 
BD Research Committee of Japan (4).
Preparation of antigen
HPV-16 L1 virus-like particle (VLP; stock number 120525-1) (5) 
was used in this study, which was supplied by EyeGene Inc. 
(Seoul, Korea). Briefly, HPV L1 VLP antigen was expressed from 
a yeast system. After cultured cells were disrupted, the lysate 
was precipitated using ammonium sulfate. Precipitated lysate 
was resuspended and then purified by cation exchange chro-
matography. The purified VLP was used in this experiment.
Enzyme-linked immunosorbent assay (ELISA)
One hundred microliters of a 20 µg/mL HPV-16 L1 VLP antigen 
solution was coated on an ELISA plate. After washing, 100 µL 
aliquots of 1/200 diluted sera from patients and normal con-
trols were added. After washing, 100 µL of a horseradish peroxi-
dase (HRP)-conjugated goat anti-human immunoglobulin G 
(IgG) polyclonal antibody (Sigma-Aldrich, St. Louis, MO, USA) 
bound to the primary antibodies. After washing away any un-
bound antibodies, 100 µL of the 1 mg/mL chromogenic sub-
strate 3,3´,5,5´-tetramethylbenzidine (KPL Inc., Gaithersburg, 
MD, USA) diluted in 100 mM sodium acetate-phosphate buffer, 
pH 4.2, containing 0.015% H2O2 was added to visualize the anti-
body complexes. Absorbance at 450 nm was measured after 3–5 
minutes with an automated plate reader (Dynatech Service Com-
pany, Inc., Alexandria, VA, USA). All the samples were analyzed 
in duplicate.
Statistical analysis
All statistical analyses were performed using SAS statistical soft-
ware (version 9.3; SAS Institute Inc., Cary, NC, USA). Discrete 
variables were described using the frequency (percentages), and 
continuous variables were reported using the median (range) 
or mean (standard deviation [SD]). The Mann-Whitney U-test 
was used for comparison of serum anti-HPV-16 antibody titers 
between the 2 independent groups. A receiver operating char-
acteristic (ROC) curve was created to determine the optimal 
anti-HPV-16 antibody titer cut-off level. Using this cut-off value 
for anti-HPV-16 antibody titer, the sensitivity and specificity were 
calculated. A univariate logistic regression analysis was performed 
to investigate possible differences in BD patients depending on 
serum anti-HPV-16 antibody titers. A Pearson’s correlation anal-
ysis was used to evaluate the relationship between the different 
study parameters. All probabilities were 2-tailed, and statistical 
significance was set at P < 0.05.
Ethics statement
This study was approved by the Institutional Review Board of 
Severance Hospital, Yonsei University College of Medicine, Seoul, 
Korea (IRB No. 4-2015-0259). All participants provided written 
informed consent. The study was conducted according to the 
Declaration of Helsinki Principles.
RESULTS
Characteristics of the study population
The detailed demographic and clinical characteristics of our sub-
jects are summarized in Table 1. The prevalence of both cardi-
nal symptoms and current symptoms at the time of blood sam-
pling was evaluated. Recurrent oral ulcers were observed in all 
patients. Other areas of involvement included genital ulcers 
(n = 87, 93.5%), skin lesions (n = 85, 91.4%), articular involve-
ment (n = 61, 65.6%), ocular involvement (n = 29, 31.2%), gas-
trointestinal lesions (n = 6, 6.5%), vascular involvement (n = 1, 
1.1%), and neurological involvement (n = 1, 1.1%). Positivity for 
human leukocyte antigen-B51 (HLA-B51), a gene allele associ-
ated with susceptibility to BD, was noted in 31 (36.5%) of 85 test-
ed patients. At the time of blood sampling, the mean BDCAF 
score was 2.25 ± 1.31 (range: 0–6), and the mean EMRAI score 
was 2.77 ± 1.26 (range: 0–7). The mean values for ESR and CRP 
were 33.77 (range: 2.0–94.0) mm/hr and 5.84 (range: 0.30–71.07) 
mg/dL, respectively.
Serum anti-HPV-16 antibody titers and determination of 
the optimal cut-off point
As shown in Fig. 1, patients with BD had significantly higher an-
tibody titers against HPV-16 (optical density [OD], 0.210–3.675; 
mean 0.992) than did healthy controls (OD, 0.248–0.762; mean 
0.517; P < 0.001). Using a ROC analysis, the cut-off value for the 
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anti-HPV antibody titer of 0.578 OD was determined to differ-
entiate BD patients from healthy controls. This cut-off value es-
tablished a sensitivity of 67.7% and specificity of 71.8% (Fig. 2).
A logistic regression analysis was performed to evaluate the va-
lidity of the cut-off value from the ROC analysis and to identify 
any associations between the different clinical manifestations 
and the serum anti-HPV-16 antibody titer in BD patients (Table 
2). BD patients were categorized into 2 groups according to the 
serum anti-HPV-16 antibody titer (≥ 0.578 OD and < 0.578 OD). 
In regards to disease activity, no meaningful differences were 
identified between these 2 groups. Patients with an anti-HPV-16 
antibody titer ≥ 0.578 OD did not possess significantly higher 
BDCAF and EMRAI scores compared to patients with a titer 
< 0.578 OD. The proportion of patients presenting with ≥ 2 ma-
jor criteria (with or without any minor criteria), who were de-
fined as having BD in the active phase according to the revised 
criteria of the BD Research Committee of Japan, was not signifi-
cantly different from that of the group with an anti-HPV-16 an-
tibody titer ≥ 0.578 OD. When we compared the clinical features 
of BD between the 2 groups, articular involvement of BD was 
more likely in patients with an anti-HPV-16 antibody titer < 0.578 
OD (P = 0.035). In addition, patients with an anti-HPV-16 anti-
Table 1. Characteristics of patients with BD
Factors BD patients (n = 93)
Demographics
Age, yr* 42.85 ± 11.25
Disease duration, mon* 20.8 ± 31.9
Gender†
   Male 22 (23.7)
   Female 71 (76.3)
Presence of symptoms on previous history†
Oral ulcers 93 (100)
Genital ulcers 87 (93.5)
Ocular involvement 29 (31.2)
Skin lesions 85 (91.4)
Arthritis 61 (65.6)
GI involvement 6 (6.5)
Vascular involvement 1 (1.1)
CNS involvement 1 (1.1)
Epididymitis 0 (0.0)
Positive pathergy test 4 (4.3)
Presence of symptoms at the time of blood collection†
Oral ulcers 70 (75.3)
Genital ulcers 23 (24.7)
Ocular involvement 12 (12.9)
Skin lesions 40 (43.0)
Arthritis 41 (44.1)
GI involvement 2 (2.2)
Vascular involvement 0 (0.0)
CNS involvement 0 (0.0)
Epididymitis 0 (0.0)
Positive pathergy test 1 (1.1)
Medications†,‡
None 32 (34.4)
Present 61 (65.6)
Activity score*
BDCAF 2.25 ± 1.31
EMRAI 2.77 ± 1.26
Positive HLA-B51§ 31 (36.5)
Laboratory investigations†,ll
ESR, mm/h 33.77 (2.0–94.0)
CRP, mg/dL 5.84 (0.30–71.07)
BD = Behçet’s disease, BDCAF = Behçet’s disease current activity form, CNS = cen-
tral nervous system, CRP = C-reactive protein, EMRAI = electronic medical record-
based activity index, ESR = erythrocyte sedimentation rate, GI = gastrointestinal, HLA- 
B51 = human leukocyte antigen-B51.
*Continuous variables = mean ± SD; †Categorical variables = number (%); ‡Patients 
treated with corticosteroids ≥ 5 mg/day, colchicine, and/or azathioprine were includ-
ed; §HLA-B51 was assessed in 85 patients; llContinuous variables: median (interquar-
tile range).
Fig. 1. Serum anti-HPV 16 antibody levels in the patients with BD. (mean OD in BD 
patients: 0.992; mean OD in normal control: 0.517). 
HPV = human papillomavirus, BD = Behçet’s disease, OD = optical density.
*P < 0.001.
Fig. 1. Serum anti-HPV 16 antibody levels in the patients with 
Behçet's disease. (mean OD in Behçet's disease patients : 0.992; 
mean OD in normal control: 0.517) P < 0.001. BD, Behçet's disease; 
OD, optical density.
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Fig. 2. Serum anti-HPV 16 antibody levels and determination of cut-off point. Cut-off 
value for Serum anti-HPV 16 antibody levels which differentiates BD patients from 
normal controls was determined by Youden index method. Youden index was 0.3954, 
cut-off point was 0.578 OD. AUC was 0.737. Sensitivity was 67.74%. Specificity was 
71.79%. 
HPV = human papillomavirus, OD = optical density, AUC = area under curve.
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body titer < 0.578 were significantly younger than patients with 
a titer ≥ 0.578 OD. However, no statistically significant differ-
ences were observed in the gender, HLA-B51 genotype, or any 
other single organ involvement between the 2 titer groups. A 
Pearson’s correlation analysis also failed to find significant dif-
ferences in anti-HPV antibody titers with respect to the disease 
activity scores or the serum levels of ESR and CRP (Table 3).
DISCUSSION
BD is a chronic, multisystem inflammatory disorder character-
ized by the recurrent involvement of mucocutaneous (oral and 
genital ulceration, erythema nodosum like skin eruption, acne-
like skin eruption, etc.), ocular, vascular, digestive, and/or ner-
vous system organs (6). Although the etiology of BD remains un-
known, the pathogenesis has been clarified by extensive studies 
of the disease’s epidemiology, clinical manifestations, and basic 
etiological research based on the intrinsic genetic and extrinsic 
triggering factors and the immunological findings (7).
 An unhygienic oral condition may be suspected as an extrin-
sic triggering factor because periodontitis, delayed teeth, chronic 
tonsillitis, etc. are frequently associated in the oral cavity of BD 
patients (8). In addition, infectious agents, especially Streptoco­
ccus sanguinis and viruses such as herpes simplex virus (HSV), 
have long been postulated as major triggering factors for BD. 
The proportion of S. sanguinis in the oral bacterial flora of BD 
patients is significantly higher than those of healthy and disease 
controls (9). Serum IgA antibody against S. sanguinis has been 
reported in patients with BD (10). The target antigen for this an-
tibody is hnRNP A2/B1 in endothelial cells, which possibly con-
tribute to the development of vasculitis in BD patients (11).
 DNA from various types of viruses, including HSV, varicella 
Table 2. Comparison of clinical features and disease activity between patient subgroups categorized according to the cut-off value for anti-HPV-16 antibody titer (0.578 OD)
Factors
Anti-HPV Ab OD < 0.578  
(n = 30)
Anti-HPV Ab OD ≥ 0.578  
(n = 63)
OR (95% CI) P value
Age, yr 45.87 ± 11.07 41.41 ± 11.23 0.942 (0.893–0.994) 0.030*
Sex
   Female 25 (83.3) 46 (73.0) 1.101 (0.279–4.348) 0.891
   Male 5 (16.7) 17 (27.0)
HLA-B51†
   Positive 11 (42.3) 20 (33.9) 0.607 (0.187–1.971) 0.406
   Negative 15 (57.7) 39 (66.1)
BDCAF 2.00 ± 1.31 2.36 ± 1.29 1.738 (0.731–4.136) 0.211
EMRAI 2.67 ± 1.27 2.83 ± 1.26 1.070 (0.470–2.436) 0.872
Presence of ≥ 2 active major symptoms
   Yes 15 (50.0) 32 (50.8) 0.303 (0.630–1.465) 0.137
   No 15 (50.0) 31 (49.2)
Genital involvement 
   Yes 29 (96.7) 58 (92.1) 0.342 (0.014–8.274) 0.509
   No 1 (3.3) 5 (7.9)
Skin involvement 
   Yes 29 (96.7) 56 (88.9) 0.291 (0.015–5.469) 0.409
   No 1 (3.3) 7 (11.1)
Ocular involvement
   Yes 6 (20.7) 23 (36.5) 1.630 (0.361–7.371) 0.525
   No 24 (80.0) 40 (63.5)
Joint involvement
   Yes 24 (80.0) 37 (58.7) 0.207 (0.048–0.896) 0.035*
   No 6 (20.0) 26 (41.3)
Data are shown as mean ± standard deviation or number (%).
HPV = human papillomavirus, OD = optical density, BDCAF = Behçet’s disease current activity form, EMRAI = electronic medical record-based activity index, HLA-B51 = human 
leukocyte antigen-B51, Ab = antibody, OR = odds ratio, CI = confidence interval.
*Differences were considered statistically significant at P < 0.05; †HLA-B51 was assessed in 85 patients.
Table 3. Correlation between serum anti-HPV-16 antibody titers, clinical variables, 
and disease activity scores
Factors BDCAF ESR CRP
Anti-HPV-16 
Ab (OD)
EMRAI r* 0.806 0.361 0.350 −0.018
P value < 0.001† < 0.001† 0.001† 0.862
BDCAF r* 0.080 0.047 0.039
P value 0.443 0.654 0.708
ESR r* 0.440 −0.049
P value < 0.001† 0.638
CRP r* −0.184
P value 0.079
Spearman analysis-no significant association with anti-HPV-16 antibody titers with 
any other values.
HPV = human papillomavirus, BDCAF = Behçet’s disease current activity form, EM-
RAI = electronic medical record-based activity index, ESR = erythrocyte sedimenta-
tion rate, CRP = C-reactive protein, Ab = antibody, OD = optical density.
*Pearson correlation coefficient; †Differences were considered statistically significant 
at P < 0.05.
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zoster virus, cytomegalovirus, Epstein-Barr virus, human her-
pes viruses 6 and 7, hepatitis virus, human immunodeficiency 
virus, and parvovirus B19 have been isolated from BD patients 
(12). Among these viruses, HSV is the leading candidate for play-
ing a potential role in the pathogenesis of BD. The presence of 
the HSV genome in peripheral blood mononuclear cells of pa-
tients with BD has been demonstrated by in situ DNA-RNA hy-
bridization techniques and polymerase chain reaction (PCR) 
studies (13). PCR studies have demonstrated significantly great-
er quantities of HSV-1 DNA in saliva, intestinal ulcers, and geni-
tal ulcers from BD patients than controls (13,14). In addition, an 
animal model created by inoculating ICR mice with HSV (15,16) 
and receiving subsequent antiviral treatment showed improv-
ing BD-like symptoms in 40% of famciclovir-treated BD mice 
(17). However, whether these 2 pathogens, HSV or S. sanguinis, 
can play an important role in the development of BD should be 
resolved.
 In this report, we demonstrated that anti-HPV-16 antibody 
titers in the sera of patients with BD are significantly increased 
when compared to those of normal controls. However, there 
were no correlations between anti-HPV-16 antibody titers and 
various parameters, including disease activity, clinical symp-
toms, or laboratory findings. However, articular involvement of 
BD may be more likely in patients with anti-HPV-16 antibody 
titer < 0.578 OD (P = 0.035). We could not explain the correla-
tion between the clinical significance of articular involvement 
and increased anti-HPV-16 titer. In addition, patients with an 
anti-HPV-16 antibody titer < 0.578 were significantly younger 
than patients with anti-HPV-16 antibody titer ≥ 0.578 OD. This 
difference in titer level might be from more active immunologi-
cal responses in the younger generation than those in the older 
generation. These 2 parameters are not important for the asso-
ciation of HPV infection with BD.
 We still do not understand the meaning of the increased anti-
HPV-16 antibody titers in the sera of patients with BD. However, 
HPV may be another possible infectious agent causing the de-
velopment of BD. As stated previously, an unhygienic oral con-
dition has been suspected as one of the extrinsic triggering fac-
tors for the development of BD. HPV infection is also associated 
with poor oral hygiene. Patients may be unable to maintain a 
clean hygienic condition because of their painful pathological 
lesions. We speculate that BD patients may be more easily in-
fected with HPV. This might be another explanation for the in-
creased anti-HPV-16 antibody titers in the sera of patients with 
BD.
 HPV antigen may be a plausible triggering factor for the de-
velopment of BD in genetically susceptible populations. This 
proposal is possible because recent studies suggest an interac-
tion between genetic factors and environmental factors, such 
as the immune response to pathogens and the gut microbiome 
composition. This may explain the role of environmental factors 
in the development of BD (7).
 Recently Tomljenovic and Shaw (18) found evidence of an 
autoimmune vasculitis potentially triggered by cross-reactive 
HPV-16 L1 antibodies binding to the walls of cerebral blood ves-
sels in postmortem brain tissue from 2 young women who suf-
fered from cerebral vasculitis-like symptoms following vaccina-
tion with the quadrivalent HPV vaccine. Lee (19) reported that 
a healthy teenage girl suffered from a sudden death in her sleep 
6 months after 3 intramuscular injections of the quadrivalent 
HPV vaccine. The postmortem blood and splenic tissue obtained 
at autopsy were found to contain HPV-16 L1 gene DNA similar 
to the HPV-16 gene DNA fragments in the quadrivalent HPV 
vaccine, suggesting a possible link. These mean HPV-16 can be 
associated with vasculitis. However, there has been no evidence 
for an HPV infection in BD patients which is thought to be vas-
culitis. To elucidate the abnormal humoral immune response 
to HPV and to analyze cellular immune response to the HPV 
antigen, additional studies should be conducted.
 Still we do not know the pathogenesis of HPV infection and 
relation between HPV infection and antibody titer. Relation be-
tween antibody titer itself and infection status or cervical lesion 
is also unclear. In one study, ELISA assays correlate good/very 
good with HPV-16/18 detected by PCR (20).
 Although the increased antibody titer does not mean that 
there is an ongoing infection, and does not reveal when the pa-
tient was infected, it can indirectly suggest that there is a history 
of exposure to the virus. And also there can be another factor 
such as sexual activity. This is the first limitation of our study. 
Second, as the study was limited by our hospital, total patient 
group and control group were relatively small. Third, data of 
sexual activity and Papanicolaou smear test to correlate with 
HPV infection is not included.
 In conclusion, we have demonstrated increased anti-HPV-16 
antibody in the serum of the patients with BD. However, the sig-
nificance of this finding remains still unclear. Further studies 
will need to be conducted to clarify whether HPV plays a role in 
the development of BD.
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